KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Chemed (CHE) over the last 17 years, with Q3 2025 value amounting to $4.8 million.

  • Chemed's Change in Accured Expenses rose 8464.48% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 4546.75%. This contributed to the annual value of $22.7 million for FY2024, which is 7769.88% up from last year.
  • As of Q3 2025, Chemed's Change in Accured Expenses stood at $4.8 million, which was up 8464.48% from $570000.0 recorded in Q2 2025.
  • In the past 5 years, Chemed's Change in Accured Expenses ranged from a high of $13.3 million in Q1 2024 and a low of -$5.1 million during Q3 2022
  • In the last 5 years, Chemed's Change in Accured Expenses had a median value of $3.0 million in 2022 and averaged $2.7 million.
  • Data for Chemed's Change in Accured Expenses shows a peak YoY increase of 32892.86% (in 2022) and a maximum YoY decrease of 24955.7% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Chemed's Change in Accured Expenses stood at -$1.4 million in 2021, then skyrocketed by 328.93% to $3.2 million in 2022, then crashed by 57.07% to $1.4 million in 2023, then surged by 219.84% to $4.4 million in 2024, then grew by 9.84% to $4.8 million in 2025.
  • Its Change in Accured Expenses stands at $4.8 million for Q3 2025, versus $570000.0 for Q2 2025 and $951000.0 for Q1 2025.